longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Piper Sandler Keeps Their Buy Rating on Amgen (AMGN)

Tip Ranks
Sep 23, 2026 at 12:25 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen today and set a price target of $457.00. According to TipRanks, Amsellem is a 5-star analyst with an average return of 15.4% and a 60.12% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, AbbVie, and Teva Pharmaceutical. In addition to Piper Sandler, Amgen also received a Buy from Scotiabank’s Louise Chen in a report issued today. However, on the same day, Truist Financial maintained a Hold rating on Amgen (NASDAQ: AMGN).

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen today and set a price target of $457.00.

According to TipRanks, Amsellem is a 5-star analyst with an average return of 15.4% and a 60.12% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, AbbVie, and Teva Pharmaceutical.

In addition to Piper Sandler, Amgen also received a Buy from Scotiabank’s Louise Chen in a report issued today. However, on the same day, Truist Financial maintained a Hold rating on Amgen (NASDAQ: AMGN).

Login to unlock32characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

Amgen

Amgen

USAMGN

-0.03%

Piper Sandler Cos

Piper Sandler Cos

USPIPR

Abbvie

Abbvie

USABBV

LongbridgeAI